Asian organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessmentopen access
- Park D.I.; Hisamatsu T.; Chen M.; Ng S.C.; Ooi C.J.; Wei S.C.; Banerjee R.; Hilmi I.N.; Jeen Y.T.; Han D.S.; Kim H.J.; Ran Z.; Wu K.; Qian J.; Hu P.-J.; Matsuoka K.; Andoh A.; Suzuki Y.; Sugano K.; Watanabe M.; Hibi T.; Puri A.S.; Yang S.-K.
- Issue Date
- Korean Association for the Study of Intestinal Diseases
- Anti-tumor necrosis factor; Consensus statement; Inflammatory bowel disease; Tuberculosis
- Intestinal Research, v.16, no.1, pp.4 - 16
- Journal Title
- Intestinal Research
- Start Page
- End Page
- Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web- based consensus voting was performed by 211 IBD specialists from 9 Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 1 of the statements comprised 2 parts: risk of TB infection Recommendaduring anti-TNF therapy, and screening for TB infection prior to commencing anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment. © 2018. Korean Association for the Study of Intestinal Diseases.
- Files in This Item
- There are no files associated with this item.
- Appears in
- 2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.